IL-8+ naïve T Cells as a Biomarker for Thymoma Identification

Sponsor
Shanghai Zhongshan Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05255965
Collaborator
(none)
310
16

Study Details

Study Description

Brief Summary

According to the existing literature reports, the misdiagnosis rate of CT is as high as 22% - 68%. Thymic cyst and lymphoma are usually misdiagnosed as thymoma, resulting in many unnecessary operations; In addition, traditional imaging technologies can also cause a missed diagnosis rate of about 7%, which is common in the missed diagnosis of asymptomatic thymoma, which delays the opportunity of treatment. Therefore, in order to accurately treat thymic tumors, the existing diagnostic methods of thymic tumors need to be further optimized.

Our previous retrospective study found that the level of IL-8 + initial T cells can well distinguish thymoma from other types of anterior mediastinal tumors, and the sensitivity and specificity are close to 95%.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: level of IL-8+ initial T cells

Detailed Description

This study is a prospective, multicenter diagnostic accuracy study. 310 patients with anterior mediastinal space occupying lesions who meet the enrollment conditions are planned to be recruited continuously. 5ml peripheral venous blood of the patients is taken before surgery or puncture biopsy and sent to the laboratory for blind detection of IL-8 + initial T cell level; Then the patient underwent anterior mediastinal tumor surgery or biopsy to obtain pathological results (gold standard for diagnosis). After the pathological results were confirmed, all cases were divided into thymoma group and non thymoma group. The sensitivity and specificity of IL-8 + initial T cells in the diagnosis of thymoma and the cutoff value of thymoma were calculated.

Study Design

Study Type:
Observational
Anticipated Enrollment :
310 participants
Observational Model:
Other
Time Perspective:
Prospective
Official Title:
IL-8+ naïve T Cells as a Biomarker for Thymoma Identification: A Prospective, Multi-center Diagnostic Accuracy Study
Anticipated Study Start Date :
Sep 1, 2022
Anticipated Primary Completion Date :
Dec 31, 2023
Anticipated Study Completion Date :
Dec 31, 2023

Outcome Measures

Primary Outcome Measures

  1. The sensitivity of levels of IL-8+ initial T cells in the diagnosis of thymoma [Through study completion, an average of 2 year]

  2. The specificity of levels of IL-8+ initial T cells in the diagnosis of thymoma [Through study completion, an average of 2 year]

  3. The cutoff value of levels of IL-8+ initial T cells in the diagnosis of thymoma [Through study completion, an average of 2 year]

Secondary Outcome Measures

  1. The sensitivity of levels of PLXND1+ initial T cells in the diagnosis of thymoma [Through study completion, an average of 2 year]

  2. The specificity of levels of PLXND1+ initial T cells in the diagnosis of thymoma [Through study completion, an average of 2 year]

  3. The sensitivity of levels of PTK7+ initial T cells in the diagnosis of thymoma [Through study completion, an average of 2 year]

  4. The specificity of levels of PTK7+ initial T cells in the diagnosis of thymoma [Through study completion, an average of 2 year]

  5. The sensitivity of levels of CR2+ initial T cells in the diagnosis of thymoma [Through study completion, an average of 2 year]

  6. The specificity of levels of CR2+ initial T cells in the diagnosis of thymoma [Through study completion, an average of 2 year]

  7. The sensitivity of enhanced CT/MRI in the diagnosis of thymoma [Through study completion, an average of 2 year]

  8. The specificity of enhanced CT/MRI in the diagnosis of thymoma [Through study completion, an average of 2 year]

  9. The sensitivity of levels of IL-8+, PLXND1+, PTK7+ and/or CR2+ initial T cells combined with enhanced CT/MRI in the diagnosis of thymoma [Through study completion, an average of 2 year]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Adult, aged 18 and above;

  • Patients with anterior mediastinal mass on imaging (chest CT or MRI);

  • The patient's anterior mediastinal mass can be diagnosed by biopsy or surgery.

Exclusion Criteria:
  • Adolescents and children under the age of 18;

  • The patient's anterior mediastinal mass can not be diagnosed by biopsy or surgery.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Shanghai Zhongshan Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Shanghai Zhongshan Hospital
ClinicalTrials.gov Identifier:
NCT05255965
Other Study ID Numbers:
  • B2021-812
First Posted:
Feb 25, 2022
Last Update Posted:
Jul 26, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Shanghai Zhongshan Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 26, 2022